Sarudzo inosarudzwa yekurapa kenza inokonzerwa nechemotherapy. Kurutsa nekusvotwa kunokonzerwa nechemotherapy (CINV) ndeimwe yemigumisiro yakaipa inotyiwa zvikuru pakati pevarwere vari kurapwa kenza, zvichikanganisa zvakanyanya kutevedzera kurapwa uye hupenyu hwavo. Sechizvarwa chitsva chevadzivisi veNK1 receptor, Fosaprepitant Dimeglumine, ine hunhu hwayo hwemishonga hwekusarudza zvakanyanya uye hukama hwakasimba, inogona kudzivirira zvakanyanya nzira yekuzivisa kurutsa inosanganisirwa nechinhu P.
Ruzivo rwekiriniki runosimbisa kuti chigadzirwa ichi chinoratidza mhedzisiro yakanaka kwazvo pakurwisa kuda kurutsa kwakanyanya uye kunonoka uye kurutsa kunokonzerwa nechemotherapy ine simba rekudzivirira chirwere (HEC) uye chemotherapy ine mwero wekudzivirira chirwere (MEC). Kupiwa mushonga mumwe chete kunogona kuita kuti pave nekurwisa chirwere kwenguva refu uye kuchishivirira zvakanaka. Kana ukasanganiswa ne5-HT3 receptor antagonists nedexamethasone, zvinovaka sisitimu yekudzivirira CINV yakakwana uye yakazara.
Kubva pakureruka kwekushandiswa kwemishonga kusvika pakugadzikana kwekushanda kwayo, Fosaprepitant Dimeglumine inopa sarudzo iri nani yekurapa, ichibatsira varwere kuti vapfuure nepakati pechirongwa chechemotherapy zvakanaka uye zvichiita kuti kurapwa kwegomarara kuve netsitsi.
Nguva yekutumira: Zvita-09-2025
